Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Author's reply to De Ponti et al.: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus".

Literature DB >> 25721223

Author's reply to De Ponti et al.: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus".

André J Scheen¹.

Abstract

Entities: Disease Species

Mesh：

Substances：

Year: 2015 PMID： 25721223 DOI： 10.1007/s40262-015-0249-3

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

Keyword Cloud
References

× No keyword cloud information.

16 in total

1. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245

2. Hepatotoxicity of alogliptin.

Authors: Elizabeth Barbehenn; Sammy Almashat; Michael Carome; Sidney Wolfe
Journal: Clin Pharmacokinet Date: 2014-11 Impact factor: 6.447

3. Alogliptin: concern about hepatotoxicity?

Authors: André J Scheen
Journal: Clin Pharmacokinet Date: 2014-11 Impact factor: 6.447

Review 4. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.

Authors: André J Scheen
Journal: Expert Opin Drug Saf Date: 2015-01-29 Impact factor: 4.250

5. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.

Authors: Ayako Suzuki; Raul J Andrade; Einar Bjornsson; M Isabel Lucena; William M Lee; Nancy A Yuen; Christine M Hunt; James W Freston
Journal: Drug Saf Date: 2010-06-01 Impact factor: 5.606

6. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

Authors: Amy G Egan; Eberhard Blind; Kristina Dunder; Pieter A de Graeff; B Timothy Hummer; Todd Bourcier; Curtis Rosebraugh
Journal: N Engl J Med Date: 2014-02-27 Impact factor: 91.245

Review 7. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors: André J Scheen
Journal: Clin Pharmacokinet Date: 2014-09 Impact factor: 6.447